Details of the Drug Reposition

General Information of This Drug (ID: DM9S5I1)

Drug Name
TC-210   DM9S5I1
Drug Type
TCR-T cell therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cholangiocarcinoma DIS71F6X 2C12.10 Phase 1/2 [1]
Non-small-cell lung cancer DISI0V1B 2C25 Phase 1/2 [1]
Peritoneal mesothelioma DISW7W4V 2C51.2 Phase 1/2 [1]
Ovarian cancer DISZJHAP 2C73 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03907852) Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer. U.S. National Institutes of Health.